WARFARIN ORION 3 mg Словакия - словацкий - ŠÚKL (Štátny ústav pre kontrolu liečiv)

warfarin orion 3 mg

orion corporation, fínsko - warfarín - 16 - anticoagulantia (fibrinolytica, antifibrinol.)

WARFARIN ORION 5 mg Словакия - словацкий - ŠÚKL (Štátny ústav pre kontrolu liečiv)

warfarin orion 5 mg

orion corporation, fínsko - warfarín - 16 - anticoagulantia (fibrinolytica, antifibrinol.)

Hotemin 20 mg Словакия - словацкий - ŠÚKL (Štátny ústav pre kontrolu liečiv)

hotemin 20 mg

egis pharmaceuticals plc - piroxikam - 29 - antirheumatica, antiphlogistica, antiuratica

Dexa-ratiopharm 4 Словакия - словацкий - ŠÚKL (Štátny ústav pre kontrolu liečiv)

dexa-ratiopharm 4

ratiopharm gmbh - dexametazón - 56 - hormona (lieČiva s hormonÁlnou aktivitou)

Flamexin 20 mg Словакия - словацкий - ŠÚKL (Štátny ústav pre kontrolu liečiv)

flamexin 20 mg

chiesi farmaceutici s.p.a., taliansko - piroxikam - 29 - antirheumatica, antiphlogistica, antiuratica

Warfarin PMCS 5 mg Словакия - словацкий - ŠÚKL (Štátny ústav pre kontrolu liečiv)

warfarin pmcs 5 mg

pro.med.cs praha a.s., Česká republika - warfarín - 16 - anticoagulantia (fibrinolytica, antifibrinol.)

Warfarin PMCS 2 mg Словакия - словацкий - ŠÚKL (Štátny ústav pre kontrolu liečiv)

warfarin pmcs 2 mg

pro.med.cs praha a.s., Česká republika - warfarín - 16 - anticoagulantia (fibrinolytica, antifibrinol.)

Azacitidine Celgene Европейский союз - словацкий - EMA (European Medicines Agency)

azacitidine celgene

celgene europe bv - azacitidín - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastické činidlá - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.